Rituximab for thyroid-associated ophthalmopathy

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 5, 2013, Pages

  Minakaran, Neda ^a   Ezra, Daniel G ^b,c  

^a WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOCORTICOID; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; RITUXIMAB; THIAMAZOLE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; CHILL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSPEPSIA; ENDOCRINE OPHTHALMOPATHY; FEVER; FLUSHING; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HEART ARREST; HUMAN; HYPERGLYCEMIA; HYPERTHYROIDISM; HYPOTENSION; INSOMNIA; MYALGIA; NASAL PRURITUS; NAUSEA; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TACHYCARDIA; THROAT DISEASE; THROAT PRURITUS; TREATMENT OUTCOME; ULCERATIVE COLITIS; URINARY TRACT INFECTION; GRAVES OPHTHALMOPATHY;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOLOGIC FACTORS;

EID: 84891680916     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009226.pub2     Document Type: Review

References (63)

1. El Fassi D, Nielsen CH, Bonnema SJ, Hasselbach HC, Hegedüs L. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. Journal of Clinical Endocrinology and Metabolism 2007;92(5):1769-72.
2. El Fassi D, Nielsen CH, Hasselbalch HC, Hegedüs L. Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid 2006;16(7):709-10.
3. El Fassi D, Nielsen CH, Kjeldsen J, Clemmensen O, Hegedüs L. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut 2008;57(5):714-5.
4. Heemstra KA, Toes RE, Sepers J, Pereira AM, Corssmit EP, Huizinga TW, et al.Rituximab in relapsing Graves' disease, a phase II study. European Journal of Endocrinology 2008;159(5):609-15.
5. Khanna D, Chong KK, Afifiyan NF, Hwang CJ, Lee DK, Garneau HC, et al.Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 2010;117(1):133-9.
6. Krassas GE, Stafilidou A, Boboridis KG. Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids. Clinical Endocrinology 2010;72(6):853-5.
7. Mitchell A, Gan E, Morris M, Johnson K, Neoh C, Dickinson A, et al.The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid refractory Graves orbitopathy. Cinical Endocrinology 2013, Jan 16; Epub ahead of print.
8. Bonara P, Vannucchi G, Campi I, Rossi S, Cantoni F, Frugoni C, et al.Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy. Clinical Reviews in Allergy and Immunology 2008;34(1):118-23.
9. Salvi M, Vannucchi G, Campi I, Currò N, Dazzi D, Simonetta S, et al.Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. European Journal of Endocrinology 2007;156(1):33-40.
10. Salvi M, Vannucchi G, Campi I, Currò N, Simonetta S, Coveli D, et al.Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clinical Immunology 2009;131(2):360-5.
11. Salvi M, Vannucchi G, Campi I, Rossi S, Bonara P, Sbrozzi F, et al.Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. European Journal of Endocrinology 2006;154(4):511-7.
12. Salvi M, Vannucchi G, Currò N, Introna M, Rossi S, Bonara P, et al.Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action. Archives of Ophthalmology 2012;130(1):122-4.
13. Silkiss RZ, Reier A, Coleman M, Lauer SA. Rituximab for thyroid eye disease. Ophthalmic Plastic and Reconstructive Surgery 2010;26(5):310-4.
14. EUCTR2011-000899-33-SE. Rituximab (RTX) therapy in steroid resistant patients or patients relapsing after intravenous steroids with active TAO Rescue RTX. www.clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2011-000899-33-SE+ (accessed 26 February 2013).
15. EUdraCT 2007-003910-33. Randomized controlled study of rituximab and steroid treatment in thyroid-associeted ophthalmopathy (TAO). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003910-33 (accessed 26 February 2013).
16. NCT00595335. Phase 2/3 study of rituximab for Graves' ophthalmopathy. clinicaltrials.gov/show/NCT00595335 (accessed 26 February 2013).
17. Bahn RS. Graves' ophthalmopathy. New England Journal of Medicine 2010;362(8):726-38.
18. Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marocci C, et al.Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid 2008;18(3):333-46.
19. Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, et al.Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism 2012;97(12):4454-63.
20. Boboridis KG, Bunce C. Surgical orbital decompression for thyroid eye disease. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI:].
21. Boissier MC, Assier E, Biton J, Denys A, Falgarone G, Bessis N. Regulatory T cells (Treg) in rheumatoid arthritis. Joint Bone Spine 2009;76(1):10-4.
22. Boye L, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Annals of Oncology 2003;14(4):520-35.
23. Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocrine Reviews 1993;14(6):747-93.
24. Eckstein AK, Johnson KT, Thanos M, Esser J, Ludgate M. Current insights into the pathogenesis of Graves' orbitopathy. Hormone and Metabolic Research 2009;41(6):456-64.
25. El Fassi D, Nielsen CH, Hasselbalch HC, Hegedüs L. Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid 2006;16(7):709-10.
26. Enzmann DR, Donaldson SS, Kriss JP. Appearance of Graves' disease on orbital computed tomography. Journal of Computer Assisted Tomography 1979;3(6):815-9.
27. European Group on Graves' Orbitopathy (EUGOGO), Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, et al.Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. European Journal of Endocrinology 2006;155(3):387-9.
28. Ezra DG, Krell, J, Rose GE, Basily M, Stebbing J, Castellano L. Transcriptome-level microarray expression profiling implicates IGF-1 and Wnt signalling dysregulation in the pathogenesis of thyroid-associated orbitopathy. Journal of Clinical Pathology 2012;65(7):608-13.
29. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
30. Han R, Smith TJ. T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1beta in orbital fibroblasts: implications for the pathogenesis of thyroid-associated ophthalmopathy. Endocrinology 2006;147(1):13-9.
31. Hasselbach HC. B-cell depletion with rituximab - a targeted therapy in Graves' disease and autoimmune thyroiditis. Immunology Letters 2003;88(1):85-6.
32. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
33. Kahaly GJ, Petrak F, Hardt J, Pitz S, Egle UT. Psychosocial morbidity of Graves' orbitopathy. Clinical Endocrinology 2005;63(4):395-402.
34. Kavanaugh A, Rosengren S, Lee SJ, Hammaker D, Firestein GS, Kalunian K, et al.Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Annual of Rheumatological Disease 2008;67(3):402-8.
35. Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010;70(11):1445-76.
36. Keren Z, Braun-Moscovici Y, Markovits D, Rozin A, Nahir M, Balbir-Gurman A, et al.Depletion of B lymphocytes in rheumatoid arthritis patients modifies IL-8-anti-IL-8 autoantibody network. Clinical Immunology 2009;113(1):108-16.
37. Krassas GE, Gogakos A, Boboridis K. Corticosteroids in the medical treatment of thyroid ophthalmopathy: when and how? Somatostatin analogues: where we stand today. Paediatric Endocrinology Reviews 2010;7(Suppl 2):204-9.
38. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 1985;314(6011):537-9.
39. Liossis SN, Sfikakis PP. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clinical Immunology 2008;127(3):280-5.
40. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, et al.Selenium and the course of mild Graves' orbitopathy. New England Journal of Medicine 2011;364(20):1920-31.
41. Marroci C, Bartanela L, Tanda ML, Manetti L, Dell'Unto E, Rocchi R, et al.Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blinded randomized study. Journal of Clinical Endocrinology and Metabolism 2001;86(8):3562-7.
42. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clinical Endocrinology 1997;47(1):9-14.
43. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, et al. Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. New England Journal of Medicine 2009;361(22):2143-52.
44. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocrine Reviews 2003;24(6):802-35.
45. Rajendram R, Lee RW, Potts MJ, Rose GE, Jain R, Olver JM, et al.Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial. Trials 2008;31(9):6.
46. Rajendram R, Bunce C, Lee RWJ, Morley AMS. Orbital radiotherapy for adult thyroid eye disease. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI:].
47. Reff ME, Carner K, Chambers KS. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83(2):435-45.
48. Reis EA, Athanazio DA, Lima I, Oliveira e Silva N, Andrade JC, Jesus RN, et al.NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis. Rheumatology International 2009;29(4):469-75.
49. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
50. Salvi M, Vannucchi G, Campi I, Rossi S, Bonara P, Sbrozzi F, et al.Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. European Journal of Endocrinology 2006;154(4):511-7.
51. Salvi M, Vannucchi G, Campi I, Currò N, Simonetta S, Coveli D, et al.Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clinical Immunology 2009;131(2):360-5.
52. Shen S, Chan A, Sfikakis PP, Hsiu Ling AL, Detorakis ET, Boboridis KG, et al.B-cell targeted therapy with rituximab for thyroid eye disease: closer to the clinic. Survey of Ophthalmology 2013;58(3):252-65.
53. Smolen JS, Keystone EC, Emery P, Breedveld FC, Betteridge N, Burmester GR, et al.Consensus Statement on the use of rituximab in patients with rheumatoid arthritis. Annals of Rheumatic Diseases 2007;66(2):143-50.
54. Sorisky A, Pardasani D, Gagnon A, Smith TJ. Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. Journal of Clinical Endrocrinology and Metabolism 1996;81(9):3428-31.
55. Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I, Leibovici L. Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis. Journal of Clinical Endocrinology and Metabolism 2009;94(8):2708-16.
56. Terwee CB, Dekker FW, Mourits MP, Gerding MN, Baldeschi L, Kalmann R, et al.Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clinical Endocrinology 2001;54(3):391-8.
57. Vignali DA, Collinson LW, Workman CJ. How regulatory T cells work. Nature Reviews Immunology 2008;8(7):523-32.
58. Villadolid MC, Yokoyama N, Izumi M, Nishikawa T, Kimura H, Ashizawa K, et al.Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. Journal of Clinical Endocrinology and Metabolism 1995;80(9):2830-3.
59. Wang SH, Baker JR. Targeting B cells in Graves' disease. Endocrinology 2006;147(10):4559-60.
60. Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. Journal of Clinical Epidemiology 1998;51(11):903-12.
61. Weetman AP. Graves' disease. New England Journal of Medicine 2000;343(17):1236-48.
62. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid 2002;12(10):855-60.
63. Zoumalan CI, Cockerham KP, Turbin RE, Volpe NJ, Kazim M, Douglas RS, et al.Efficacy of corticosteroids and external beam radiation in the management of moderate to severe thyroid eye disease. Journal of Neuro-Opthalmology 2007;27(3):205-14.